Almirall, S.A. (ALM) and etherna are teaming up to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
The alliance combines and leverages etherna’s proprietary mRNA capabilities and lipid nanoparticle (LNP) formulations with Almirall’s medical dermatology expertise to accelerate discovery of novel treatment options.
Etherna and Almirall will work collaboratively on the research activities, while Almirall will lead clinical development and commercialization. Under the terms of the agreement, etherna will receive upfront and technology access payments. In addition, etherna is eligible to receive success-based development and commercial milestone payments contingent upon launch and commercial success of multiple products, as well as tiered royalties based upon future global sales. Further financial details were not disclosed.
“Almirall and etherna share the vision that intradermal application of LNP-formulated mRNA is a highly promising strategy to bring novel, efficacious new treatment options that will deliver huge benefits to patients,” says Bernard Sagaert, CEO of etherna, in a news release.
